QurAlis chief scientific officer Dan Elbaum (center) works with researchers in the ALS biotech’s Cambridge, MA lab.
ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA approval of Amylyx Pharmaceuticals’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
